Patents by Inventor Nobuhiko Kawanishi
Nobuhiko Kawanishi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8614221Abstract: The instant invention provides for substituted fused naphthyridine derivatives that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.Type: GrantFiled: March 10, 2010Date of Patent: December 24, 2013Assignees: Merck Sharp & Dohme Corp., MSD K.K.Inventors: Weiming Fan, Thomas F. N. Haxell, Matthew G. Jenks, Nobuhiko Kawanishi, Shuliang Lee, Hao Liu, Michael J. Malaska, Joseph A. Moore, III, Yoshio Ogino, Yu Onozaki, Bharathi Pandi, Michael R. Peel, Toshihiro Sakamoto, Tony Siu
-
Patent number: 8536193Abstract: The instant invention provides for substituted [1,2,4]triazolo[4,3-a]-1,5-naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms, preferably Akt1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity, especially Akt1 by administering the compound to a patient in need of treatment of cancer.Type: GrantFiled: May 27, 2009Date of Patent: September 17, 2013Assignees: Merck Sharp & Dohme Corp., MSD K.K.Inventors: Hidetomo Furuyama, Yasuhiro Goto, Nobuhiko Kawanishi, Mark E. Layton, Takashi Mita, Yoshio Ogino, Yu Onozaki, Michael A. Rossi, Toshihiro Sakamoto, Philip E. Sanderson, Jiabing Wang
-
Patent number: 8519136Abstract: The present invention relates to a compound of formula I: wherein: R1 is a hydrogen atom, F, CN, etc.; R2 is CO, SO2, etc.; R3 is a phenyl which may be substituted; X1, X2, and X3 each independently CH, N, etc. provided, however, that among X1, X2 and X3, the number of nitrogen is 0 or 1; W is the following residue: wherein: W1, W2, and W3 each independently CH, N, etc., or a pharmaceutically acceptable salt or ester thereof.Type: GrantFiled: February 18, 2009Date of Patent: August 27, 2013Assignee: MSD K.K.Inventors: Tetsuya Kato, Nobuhiko Kawanishi, Takashi Mita, Katsumasa Nonoshita, Mitsuru Ohkubo
-
Patent number: 8492397Abstract: The present invention relates to a compound of Formula (I): wherein R1 is H or C1-2 alkyl; R2 is H or C1-3 alkyl; R3 and R4 are each independently H or C1-2 alkyl, where the alkyl may be substituted with one to three of the same or different substituents selected from R10; R5 is H, hydroxy, C1-2 alkyl, or OCH3; and R10 is F or Cl, or a pharmaceutically acceptable salt or ester thereof.Type: GrantFiled: March 12, 2010Date of Patent: July 23, 2013Assignees: Vertex Pharmaceuticals Incorporated, MSD K.K.Inventors: Hayley Binch, Masaya Hashimoto, Toshiharu Iwama, Nobuhiko Kawanishi, Michael Mortimore, Mitsuru Ohkubo, Tomoko Sunami
-
Patent number: 8263632Abstract: The present invention relates to a compound of Formula (I): wherein: n is 0 or 1; X is 0 or CH2; R1 is H or C1-2 alkyl; R2 is H or C1-3 alkyl; R3 and R4 are each independently H or C1-2 alkyl, where the alkyl may be substituted with one to three of the same or different substituents selected from R10; R5 is H or OCH3; R10 is F or Cl; or a pharmaceutically acceptable salt or ester thereofType: GrantFiled: March 15, 2010Date of Patent: September 11, 2012Assignees: Vertex Pharmaceuticals Incoporated, MSD K.K.Inventors: Toshiharu Iwama, Nobuhiko Kawanishi, Michael Mortimore, Mitsuru Ohkubo, Tomoko Sunami
-
Patent number: 8207169Abstract: The compounds of Formula D are of the class of triazolo-pyrido-pyrazines which are inhibitors of AKT useful for the treatment of cancerType: GrantFiled: May 28, 2009Date of Patent: June 26, 2012Assignee: MSD K.K.Inventors: Hidetomo Furuyama, Yasuhiro Goto, Nobuhiko Kawanishi, Mark E. Layton, Takashi Mita, Akira Naya, Yoshio Ogino, Yu Onozaki, Kevin J. Rodzinak, Toshihiro Sakamoto, Philip E. Sanderson, Jiabing Wang
-
Publication number: 20120029004Abstract: The present invention relates to a compound of Formula (I): wherein: R1 is H or C1-2 alkyl; R2 is H or C1-3 alkyl; R3 and R4 are each independently H or C1-2 alkyl, where the alkyl may be substituted with one to three of the same or different substituents selected from R10; R5 is H, hydroxy, C1-2 alkyl, or OCH3; and R10 is F or Cl, or a pharmaceutically acceptable salt or ester thereof.Type: ApplicationFiled: March 12, 2010Publication date: February 2, 2012Inventors: Hayley Binch, Masaya Hashimoto, Toshiharu Iwama, Nobuhiko Kawanishi, Michael Mortimore, Mitsuru Ohkubo, Tomoko Sunami
-
Patent number: 8101621Abstract: The present invention relates to a compound of general formula I: wherein: n1 and n2 are the same or different, and are 0 or 1; R is aryl, heteroaryl, etc.; Re is hydrogen atom or lower alkyl; two groups selected from four groups consisting of (i) either one of Ra1 and Ra1?, (ii) either one of Ra2 and Ra2?, (iii) either one of Rb1 and Rb1?, and (iv) either one of Rb2 and Rb2?, are combined to form —(CH2)n— where n is 1, 2 or 3; and among Ra1, Ra1?, Ra2, Ra2?, Rb1, Rb1?, Rb2 and Rb2?, the groups which do not form —(CH2)n— are each independently hydrogen atom, etc.; X1, X2, X3 and X4 are each independently CH, N, etc.; Y1, Y2, Y3 and Y4 are the same or different and are CH or N, etc.; W is a 5-membered aromatic heterocyclic group, or a pharmaceutically acceptable salt or ester thereof.Type: GrantFiled: April 25, 2007Date of Patent: January 24, 2012Assignee: MSD K.K.Inventors: Tetsuya Kato, Nobuhiko Kawanishi, Takashi Mita, Keita Nagai, Katsumasa Nonoshita, Mitsuru Ohkubo
-
Publication number: 20120015940Abstract: The present invention relates to a compound of Formula (I): wherein: n is 0 or 1; X is O or CH2; R1 is H or C1-2 alkyl; R2 is H or C1-3 alkyl; R3 and R4 are each independently H or C1-2 alkyl, where the alkyl may be substituted with one to three of the same or different substituents selected from R10 R5 is H or OCH3; R10 is F or Cl; or a pharmaceutically acceptable salt or ester thereof.Type: ApplicationFiled: March 15, 2010Publication date: January 19, 2012Inventors: Toshiharu Iwama, Nobuhiko Kawanishi, Michael Mortimore, Mitsuru Ohkubo, Tomoko Sunami
-
Publication number: 20120004240Abstract: The instant invention provides for substituted fused naphthyridine derivatives that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.Type: ApplicationFiled: March 3, 2010Publication date: January 5, 2012Inventors: Weiming Fan, Thomas F.N. Haxell, Matthew G. Jenks, Nobuhiko Kawanishi, Shuliang Lee, Hao Liu, Michael J. Malaska, Joseph A. Moore, III, Yoshio Ogino, Yu Onozaki, Bharathi Pandi, Michael R. Peel, Toshihiro Sakamoto, Tony Siu
-
Publication number: 20110092511Abstract: The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms, preferably Akt1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity especially Akt1 by administering the compound to a patient in need of treatment of cancer.Type: ApplicationFiled: May 28, 2009Publication date: April 21, 2011Inventors: Hidetomo Furuyama, Yasuhiro Goto, Nobuhiko Kawanishi, Mark E. Layton, Takashi Mita, Akira Naya, Yoshio Ogino, Yu Onozaki, Kevin J. Rodzinak, Toshihiro Sakamoto, Philip E. Sanderson, Jiabing Wang
-
Publication number: 20110082135Abstract: The instant invention provides for substituted [1,2,4]triazolo[4,3-a]-1,5-naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms, preferably Akt1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity, especially Akt1 by administering the compound to a patient in need of treatment of cancer.Type: ApplicationFiled: May 27, 2009Publication date: April 7, 2011Inventors: Hidetomo Furuyama, Yasuhiro Goto, Nobuhiko Kawanishi, Mark E. Layton, Takashi Mita, Yoshio Ogino, Yu Onozaki, Michael A. Rossi, Toshihiro Sakamoto, Philip E. Sanderson, Jiabing Wang
-
Patent number: 7915263Abstract: The present invention relates to a compound of formula I: wherein: R1 is a hydrogen atom, F, CN, etc.; R1? is a hydrogen atom or lower alkyl which may be substituted; R2 is O, S, SO, SO2, etc.; R3 is a phenyl which may be substituted; X1, X2, and X3 each independently CH, N, etc. provided, however, that among X1, X2 and X3, the number of nitrogen is 0 or 1; W is the following residue: wherein: W1, W2, and W3 each independently CH, N, etc., or a pharmaceutically acceptable salt or ester thereof.Type: GrantFiled: August 29, 2007Date of Patent: March 29, 2011Assignee: Banyu Pharmaceutical Co., Ltd.Inventors: Yoshikazu Iwasawa, Tetsuya Kato, Nobuhiko Kawanishi, Kouta Masutani, Takashi Mita, Katsumasa Nonoshita, Mitsuru Ohkubo
-
Publication number: 20110003833Abstract: The present invention relates to a compound of formula I: wherein: R1 is a hydrogen atom, F, CN, etc.; R2 is CO, SO2, etc.; R3 is a phenyl which may be substituted; X1, X2, and X3 each independently CH, N, etc. provided, however, that among X1, X2 and X3, the number of nitrogen is 0 or 1; W is the following residue: wherein: W1, W2, and W3 each independently CH, N, etc., or a pharmaceutically acceptable salt or ester thereof.Type: ApplicationFiled: February 18, 2009Publication date: January 6, 2011Inventors: Tetsuya Kato, Nobuhiko Kawanishi, Takashi Mita, Katsumasa Nonoshita, Mitsuru Ohkubo
-
Patent number: 7834018Abstract: The present invention relates to a compound represented by the general formula (I): wherein m1 and m2 are 1, 2, or 3; n1 and n2 are 0 or 1; i is an integer of any of 1 to m1; j is an integer of 1 to m2; R is aryl, heteroaryl, or cycloalkyl any of which may be substituted; Rai and Rai? is hydrogen atom, etc. and Rbj and Rbj? is hydrogen atom, etc.; Rc, Rd, and Re are hydrogen atom, etc; X1 is CH, CX1a, or N; X2 is CH, N, etc.; X3 is CH, N, etc.; X4 is CH or N; Y1, Y2, and Y3 are each independently CH or N; Z1 and Z2 are each independently CH or N; W is a 5-membered aromatic heterocyclic group such as pyrazolyl, thiazolyl, etc., or a pharmaceutically acceptable salt or ester thereof; a pharmaceutical composition or antitumor agent containing the same; and combinations of the antitumor agent with other antitumor agent(s).Type: GrantFiled: December 3, 2008Date of Patent: November 16, 2010Assignee: Banyu Pharmaceutical Co., LtdInventors: Mitsuru Ohkubo, Tetsuya Kato, Nobuhiko Kawanishi, Takashi Mita, Toshiyasu Shimomura
-
Patent number: 7709475Abstract: The present invention relates to a compound represented by Formula [I]: wherein X is O, S, NH or CH2; Y1, Y2, Y3, Y4 and Y5, which may be identical or different, are each CH or N; however, at least one of Y1, Y2, Y3, Y4 and Y5 is N; Z1 and Z2, which may be identical or different, are each CH or N; n is an integer from 1 to 3; R1 is a C3-C8 cycloalkyl group, a C6-C10 aryl group, an aliphatic heterocyclic ring or an aromatic heterocyclic ring, or a bicyclic aliphatic saturated hydrocarbon group; R2 and R3, which may be identical or different, are each a hydrogen atom, a lower alkyl group, a lower alkenyl group, a C3-C8 cycloalkyl group, a C6-C10 aryl group, an aromatic heterocyclic ring, or the like; and R4 is a hydrogen atom, a lower alkyl group, a C3-C6 cycloalkyl group or the like, or a pharmaceutically acceptable salt or ester thereof, and a selective inhibitor against Cdk4 and/or Cdk6 or an anticancer agent containing the compound or a pharmaceutically acceptable salt or ester thereof.Type: GrantFiled: May 19, 2005Date of Patent: May 4, 2010Assignee: Banyu Pharmaceutical Co., Ltd.Inventors: Yoshikazu Iwasawa, Jun Shibata, Tadashi Shimamura, Hideki Kurihara, Takashi Mita, Nobuhiko Kawanishi, Takashi Hashihayata, Mikako Kawamura, Takeshi Sagara, Sachie Arai, Hiroshi Hirai
-
Publication number: 20100016335Abstract: The present invention relates to a compound of formula I: wherein: R1 is a hydrogen atom, F, CN, etc.; R1? is a hydrogen atom or lower alkyl which may be substituted; R2 is O, S, SO, SO2, etc.; R3 is a phenyl which may be substituted; X1, X2, and X3 each independently CH, N, etc. provided, however, that among X1, X2 and X3, the number of nitrogen is 0 or 1; W is the following residue: wherein: W1, W2, and W3 each independently CH, N, etc., or a pharmaceutically acceptable salt or ester thereof.Type: ApplicationFiled: August 29, 2007Publication date: January 21, 2010Inventors: Yoshikazu Iwasawa, Tetsuya Kato, Nobuhiko Kawanishi, Kouta Masutani, Takashi Mita, Katsumasa Nonoshita, Mitsuru Ohkubo
-
Publication number: 20090192174Abstract: The present invention relates to a compound of general formula I: wherein: n1 and n2 are the same or different, and are 0 or 1; R is aryl, heteroaryl, etc.; Re is hydrogen atom or lower alkyl; two groups selected from four groups consisting of (i) either one of Ra1 and Ra1?, (ii) either one of Ra2 and Ra2?, (iii) either one of Rb1 and Rb1?, and (iv) either one of Rb2 and Rb2?, are combined to form —(CH2)n— where n is 1, 2 or 3; and among Ra1, Ra1?, Ra2, Ra2?, Rb1, Rb1?, Rb2 and Rb2?, the groups which do not form —(CH2)n— are each independently hydrogen atom, etc.; X1, X2, X3 and X4 are each independently CH, N, etc.; Y1, Y2, Y3 and Y4 are the same or different and are CH or N, etc.; W is a 5-membered aromatic heterocyclic group, or a pharmaceutically acceptable salt or ester thereof.Type: ApplicationFiled: April 25, 2007Publication date: July 30, 2009Applicant: BANYU PHARMACEUTICAL CO., LTD.Inventors: Tetsuya Kato, Nobuhiko Kawanishi, Takashi Mita, Keita Nagai, Katsumasa Nonoshita, Mitsuru Ohkubo
-
Publication number: 20090149470Abstract: The present invention relates to a compound represented by the general formula (I): wherein m1 and m2 are 1, 2, or 3; n1 and n2 are 0 or 1; i is an integer of any of 1 to m1; j is an integer of 1 to m2; R is aryl, heteroaryl, or cycloalkyl any of which may be substituted; Rai and Rai? is hydrogen atom, etc. and Rbj and Rbj? is hydrogen atom, etc.; Rc, Rd, and Re are hydrogen atom, etc; X1 is CH, CX1a, or N; X2 is CH, N, etc.; X3 is CH, N, etc.; X4 is CH or N; Y1, Y2, and Y3 are each independently CH or N; Z1 and Z2 are each independently CH or N; W is a 5-membered aromatic heterocyclic group such as pyrazolyl, thiazolyl, etc., or a pharmaceutically acceptable salt or ester thereof; a pharmaceutical composition or antitumor agent containing the same; and combinations of the antitumor agent with other antitumor agent(s).Type: ApplicationFiled: December 3, 2008Publication date: June 11, 2009Inventors: Mitsuru Ohkubo, Tetsuya Kato, Nobuhiko Kawanishi, Takashi Mita, Toshiyasu Shimomura
-
Publication number: 20090137597Abstract: A quinoxalinone derivative of the formula (I): or a pharmaceutically acceptable salt or ester thereof, wherein; X is NH, S or the like; Y is O or the like; the partial structure is, for example, the formula: B1, B2, . . . , Bn?1 and Bn, (in which n is 4, 5 or 6) are each independently CH, N or the like; B?1, B?2, . . . , B?n?1 and B?n (in which n is 4, 5 or 6) are each independently hydrogen or the like; and R is hydrogen, lower alkyl or the like.Type: ApplicationFiled: April 21, 2008Publication date: May 28, 2009Inventors: Hiroshi Hirai, Nobuhiko Kawanishi, Masaaki Hirose, Tetsuya Sugimoto, Kaori Kamijyo, Jun Shibata, Kouta Masutani